{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:23:49Z","timestamp":1794353029847,"version":"4.9.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although beta-amyloid (A\u03b2) and phosphorylated tau remain the preferred targets for disease-modifying treatments (DMT) against Alzheimer\u2019s disease (AD), part of the pathophysiological mechanisms of cognitive impairment are related to neuroinflammation and oxidative stress. In mild cognitive impairment (MCI), a prodromal stage of AD and other neurodegenerative conditions, the joint appearance of inflammation, oxidative stress, and metabolic alterations are the common pathways of neurotoxicity and neurodegeneration. The standardized extract of\n                    <jats:italic>Ginkgo biloba<\/jats:italic>\n                    EGb 761 interferes with the pathogenic mechanisms involved in both the development of cognitive impairment due to AD and that of vascular origin. The primary objective of this study is to compare changes in the levels of blood markers of inflammation and oxidative stress after treatment with EGb 761 in a cohort of 100 patients with MCI. In addition, we aim to assess changes in these blood markers during an additional 12-month extension phase in which patients in the control group will also receive EGb 761 and patients in the active group will extend their treatment duration. Secondary objectives include comparing changes in neuropsychiatric and cognitive test scores between the baseline (v0) and 12-month visits (v2).  This study is a Phase IV, single-center, randomized, open-label, parallel-group clinical trial consisting of the 12-month follow-up of a cohort of participants with MCI [Global Deterioration Scale (GDS)\u2009=\u20093] and an extension with an additional 12-month follow-up. During the first 12\u00a0months, participants will be randomized into two arms: in one arm, patients will receive 1 daily tablet of EGb 761 240\u00a0mg orally (study group,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200950), while in the other arm, patients will not receive EGb 761 and will undergo the same assessments as the treated group (control group,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200950). After the first 12\u00a0months of the study, patients in the EGb 761-treated group will continue treatment, and patients in the control group will be offered one EGb 761 240\u00a0mg tablet per day orally. All participants will be monitored for an additional 12\u00a0months. A battery of blood markers of inflammation and oxidative stress will be quantified at v0, v1, v2, v3, and v4. The Olink Proteomics panel of inflammation markers (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.olink.com\/products\/inflammation\/\">https:\/\/www.olink.com\/products\/inflammation\/<\/jats:ext-link>\n                    ) will be used to evaluate 92 proteins associated with inflammatory diseases and related biological processes. The second panel measures 92 proteins involved in neurological processes. At v0, v2, and v4, neuropsychological and neurological evaluations will be conducted in addition to vital signs and anthropometric studies using a body composition monitor with bioimpedance technology (Tanita). Sixty percent of the 100 MCI patients recruited were women. The mean age was 73.1\u00a0years, and the mean time between symptom onset and MCI diagnosis was 2.9\u00a0years. The mean Mini-Mental State Examination (MMSE) score was 26.7. Depressive and anxiety disorders, as well as vascular risk factors, were the most frequent comorbidities among the cohort. The study is still ongoing, and results for the first year of treatment (v0, v1, v2) are expected by 2023. Individuals with MCI have an elevated risk of developing dementia. EGb 761 is used worldwide for the symptomatic treatment of cognitive disorders due to its neuroprotective effects. In experimental models and clinical observational studies, EGb 761 has shown strong antioxidant and anti-inflammatory activity. As a result, this study has been proposed to evaluate the antioxidant and anti-inflammatory effects on plasma markers and their potential clinical correlation with the progression of cognitive decline in patients with MCI.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial registration:<\/jats:bold>\n                    Registro Espa\u00f1ol de estudios cl\u00ednicos (REec) number 2020-003776-41, ClinicalTrials.gov Identifier: NCT05594355.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-32515-6","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T07:02:40Z","timestamp":1680505360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["A randomized, open-label clinical trial in mild cognitive impairment with EGb 761 examining blood markers of inflammation and oxidative stress"],"prefix":"10.1038","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05594355","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Xavier","family":"Morat\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Marqui\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Tartari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asunci\u00f3n","family":"Lafuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Abdelnour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Alegret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Jofresa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Buend\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ibarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Diego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Cuevas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Ca\u00f1ada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Calvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester Esteban-De","family":"Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"P\u00e9rez-Cord\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Sanabria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"de Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Nu\u00f1ez-Llaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelina","family":"Orellana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Montrreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Ca\u00f1abate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mait\u00e9e","family":"Rosende-Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urszula","family":"Bojaryn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Ricciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M.","family":"Ariton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalia","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Lleonart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Alarc\u00f3n-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariola","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Preckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Tantinya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribel","family":"Ramis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Belen","family":"Nogales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Seguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Pytel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergi","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miren","family":"Gurruchaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00eds","family":"T\u00e1rraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agust\u00edn","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Boada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"issue":"12","key":"32515_CR1","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1001\/archneur.58.12.1985","volume":"58","author":"RC Petersen","year":"2001","unstructured":"Petersen, R. C. et al. Current concepts in mild cognitive impairment. Arch. Neurol. 58(12), 1985\u20131992. https:\/\/doi.org\/10.1001\/archneur.58.12.1985 (2001).","journal-title":"Arch. Neurol."},{"issue":"3","key":"32515_CR2","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","volume":"90","author":"RC Petersen","year":"2018","unstructured":"Petersen, R. C. et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 90(3), 126\u2013135. https:\/\/doi.org\/10.1212\/WNL.0000000000004826 (2018) (Epub 2017 Dec 27).","journal-title":"Neurology"},{"issue":"3","key":"32515_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3233\/JAD-2011-110740.4.-","volume":"27","author":"GB William","year":"2011","unstructured":"William, G. B. et al. Mild cognitive impairment: Prodromal Alzheimer\u2019s disease or something else? Comparative study. J. Alzheimers Dis. 27(3), 543\u2013551. https:\/\/doi.org\/10.3233\/JAD-2011-110740.4.- (2011).","journal-title":"J. Alzheimers Dis."},{"issue":"3","key":"32515_CR4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3233\/JAD-122002","volume":"34","author":"A Espinosa","year":"2013","unstructured":"Espinosa, A. et al. A longitudinal follow-up of 550 mild cognitive impairment patients: Evidence for large conversion to dementia rates and detection of major risk factors involved. J. Alzheimers Dis. 34(3), 769\u2013780. https:\/\/doi.org\/10.3233\/JAD-122002 (2013).","journal-title":"J. Alzheimers Dis."},{"key":"32515_CR5","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/alz.12480","volume":"18","author":"T Duygu","year":"2022","unstructured":"Duygu, T. et al. Contribution of Alzheimer\u2019s biomarkers and risk factors to cognitive impairment and decline across the Alzheimer\u2019s disease continuum. Alzheimer\u2019s Dement. 18, 1370\u20131382. https:\/\/doi.org\/10.1002\/alz.12480 (2022).","journal-title":"Alzheimer\u2019s Dement."},{"issue":"3","key":"32515_CR6","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3233\/JAD-122002","volume":"34","author":"A Espinosa","year":"2013","unstructured":"Espinosa, A. et al. A longitudinal follow-up of 550 mild cognitive impairment patients: Evidence for large conversion to dementia rates and detection of major risk factors involved. J. Alzheimers Dis. 34(3), 769\u2013780. https:\/\/doi.org\/10.3233\/JAD-122002 (2013).","journal-title":"J. Alzheimers Dis."},{"issue":"2","key":"32515_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3233\/JAD-161223","volume":"57","author":"A Espinosa","year":"2017","unstructured":"Espinosa, A. et al. Cognitive composites domain scores related to neuroimaging biomarkers within probable-amnestic mild cognitive impairment-storage subtype. J. Alzheimers Dis. 57(2), 447\u2013459. https:\/\/doi.org\/10.3233\/JAD-161223 (2017).","journal-title":"J. Alzheimers Dis."},{"key":"32515_CR8","doi-asserted-by":"publisher","first-page":"101639","DOI":"10.1016\/j.arr.2022.101639","volume":"79","author":"G Nantachai","year":"2022","unstructured":"Nantachai, G., Vasupanrajit, A., Tunvirachaisakul, C., Solmi, M. & Maes, M. Oxidative stress and antioxidant defenses in mild cognitive impairment: A systematic review and meta-analysis. Ageing Res. Rev. 79, 101639. https:\/\/doi.org\/10.1016\/j.arr.2022.101639 (2022) (Epub 2022 May 7).","journal-title":"Ageing Res. Rev."},{"key":"32515_CR9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","volume":"4","author":"JW Kinneya","year":"2018","unstructured":"Kinneya, J. W. et al. Inflammation as a central mechanism in Alzheimer\u2019s disease. Alzheimer\u2019s Dementia Transl. Res. Clin. Interventions 4, 575\u2013590. https:\/\/doi.org\/10.1016\/j.trci.2018.06.014 (2018).","journal-title":"Alzheimer\u2019s Dementia Transl. Res. Clin. Interventions"},{"issue":"2019","key":"32515_CR10","doi-asserted-by":"publisher","first-page":"9695412","DOI":"10.1155\/2019\/9695412","volume":"12","author":"I Lejri","year":"2019","unstructured":"Lejri, I., Agapouda, A., Grimm, A. & Eckert, A. Mitochondria- and oxidative stress-targeting substances in cognitive decline-related disorders: From molecular mechanisms to clinical evidence. Oxid. Med. Cell Longev. 12(2019), 9695412. https:\/\/doi.org\/10.1155\/2019\/9695412 (2019).","journal-title":"Oxid. Med. Cell Longev."},{"issue":"4","key":"32515_CR11","doi-asserted-by":"publisher","first-page":"18003","DOI":"10.1038\/nrdp.2018.3","volume":"15","author":"WM Van der Flier","year":"2018","unstructured":"Van der Flier, W. M. et al. Vascular cognitive impairment. Nat. Rev. Dis. Primers 15(4), 18003. https:\/\/doi.org\/10.1038\/nrdp.2018.3 (2018).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"32515_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2017.1308552","author":"WE M\u00fcller","year":"2017","unstructured":"M\u00fcller, W. E. et al. Therapeutic efficacy of the Ginkgo special extract EGb761 within the framework of the mitochondrial cascade hypothesis of Alzheimer\u2019s disease. World J. Biol. Psychiatry https:\/\/doi.org\/10.1080\/15622975.2017.1308552 (2017).","journal-title":"World J. Biol. Psychiatry"},{"issue":"Suppl 1","key":"32515_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0211-139X(16)30140-8","volume":"51","author":"C Fern\u00e1ndez-Viadero","year":"2016","unstructured":"Fern\u00e1ndez-Viadero, C., Jim\u00e9nez-Sanz, M., Fern\u00e1ndez-P\u00e9rez, A., Verduga V\u00e9lez, R. & Crespo, S. D. Inflammation and oxidation: Predictive and\/or causative factors. Rev. Esp. Geriatr. Gerontol. 51(Suppl 1), 27\u201333. https:\/\/doi.org\/10.1016\/S0211-139X(16)30140-8 (2016).","journal-title":"Rev. Esp. Geriatr. Gerontol."},{"issue":"9","key":"32515_CR14","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.2147\/CIA.S72728","volume":"28","author":"S Gauthier","year":"2014","unstructured":"Gauthier, S. & Schlaefke, S. Efficacy and tolerability of Ginkgo biloba extract EGb 761 in dementia: A systematic review and meta-analysis of randomized placebo-controlled trials. Clin. Interv. Aging 28(9), 2065\u20132077. https:\/\/doi.org\/10.2147\/CIA.S72728 (2014).","journal-title":"Clin. Interv. Aging"},{"key":"32515_CR15","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1565830","author":"K Sch\u00f6tz","year":"2015","unstructured":"Sch\u00f6tz, K., Waimer, F. & Koch, E. Principal component analysis of production batches of the Ginkgo biloba extract EGb 761 over a period of 10 years on the basis of routine quality control parameters. Planta Med. https:\/\/doi.org\/10.1055\/s-0035-1565830 (2015).","journal-title":"Planta Med."},{"issue":"6","key":"32515_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.phrs.2007.09.011","volume":"56","author":"R Abdel-Kader","year":"2007","unstructured":"Abdel-Kader, R. et al. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol. Res. 56(6), 493\u2013502. https:\/\/doi.org\/10.1016\/j.phrs.2007.09.011 (2007).","journal-title":"Pharmacol. Res."},{"issue":"10","key":"32515_CR17","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1096\/fj.06-7649com","volume":"21","author":"F Tchantchou","year":"2007","unstructured":"Tchantchou, F., Xu, Y., Wu, Y., Christen, Y. & Luo, Y. EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer\u2019s disease. FASEB J. 21(10), 2400\u20132408. https:\/\/doi.org\/10.1096\/fj.06-7649com (2007).","journal-title":"FASEB J."},{"issue":"50","key":"32515_CR18","doi-asserted-by":"publisher","first-page":"13102","DOI":"10.1523\/JNEUROSCI.3448-06.2006","volume":"26","author":"Y Wu","year":"2006","unstructured":"Wu, Y. et al. Amyloid-\u03b2-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J. Neurosci. 26(50), 13102\u201313113. https:\/\/doi.org\/10.1523\/JNEUROSCI.3448-06.2006 (2006).","journal-title":"J. Neurosci."},{"issue":"4","key":"32515_CR19","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.clnu.2003.10.010","volume":"23","author":"SY Huang","year":"2004","unstructured":"Huang, S. Y., Jeng, C., Kao, S. C., Yu, J. J. & Liu, D. Z. Improved haemorrheological properties by Ginkgo biloba extract (EGb 761) in type 2 diabetes mellitus complicated with retinopathy. Clin. Nutr. 23(4), 615\u2013621. https:\/\/doi.org\/10.1016\/j.clnu.2003.10.010 (2004).","journal-title":"Clin. Nutr."},{"issue":"10","key":"32515_CR20","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/gps.4103","volume":"29","author":"SI Gavrilova","year":"2014","unstructured":"Gavrilova, S. I., Preuss, U. W. & Wong, J. W. M. Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: A randomized, placebo-controlled, double-blind, multicenter trial. Int. J. Geriatr. Psychiatry 29(10), 1087\u20131095. https:\/\/doi.org\/10.1002\/gps.4103 (2014) (Epub 2014 Mar 16).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"32515_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4236\/nm.2011.21007","volume":"2","author":"B Grass-Kapanke","year":"2011","unstructured":"Grass-Kapanke, B. & Busmane, A. Effects of Ginkgo Biloba special extract EGb 761 in very mild cognitive impairment (vMCI). Neurosci. Med. 2, 48\u201356. https:\/\/doi.org\/10.4236\/nm.2011.21007 (2011).","journal-title":"Neurosci. Med."},{"issue":"2","key":"32515_CR22","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3233\/JAD-140837","volume":"43","author":"MS Tan","year":"2015","unstructured":"Tan, M. S. et al. Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: A systematic review and meta-analysis. J. Alzheimers Dis. 43(2), 589\u2013603. https:\/\/doi.org\/10.3233\/JAD-140837 (2015).","journal-title":"J. Alzheimers Dis."},{"issue":"3","key":"32515_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1017\/S1041610217001892","volume":"30","author":"E Savaskan","year":"2018","unstructured":"Savaskan, E., Mueller, H., Hoerr, R., von Gunten, A. & Gauthier, S. Treatment effects of Ginkgo biloba extract EGb 761 on the spectrum of behavioral and psychological symptoms of dementia: Meta-analysis of randomized controlled trials. Int. Psychogeriatr. 30(3), 285\u2013293. https:\/\/doi.org\/10.1017\/S1041610217001892 (2018).","journal-title":"Int. Psychogeriatr."},{"key":"32515_CR24","doi-asserted-by":"crossref","unstructured":"Gil, P. Modificaciones en los patrones inflamatorios perifericos en pacientes con deterioro cognitivo leve mediante EGb 761. Vol. 53. N\u00fam. S1. N\u00famero especial: 60 Congreso de la Sociedad Espa\u00f1ola de Geriatr\u00eda y Gerontolog\u00eda p\u00e1ginas 99\u2013100 (Junio 2018).","DOI":"10.1016\/j.regg.2018.04.241"},{"issue":"3","key":"32515_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen, R. C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256(3), 183\u2013194. https:\/\/doi.org\/10.1111\/j.1365-2796.2004.01388.x (2004).","journal-title":"J. Intern. Med."},{"issue":"9","key":"32515_CR26","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1176\/ajp.139.9.1136","volume":"139","author":"B Reisberg","year":"1982","unstructured":"Reisberg, B., Ferris, S. H., de Leon, M. J. & Crook, T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am. J. Psychiatry 139(9), 1136\u20131139. https:\/\/doi.org\/10.1176\/ajp.139.9.1136 (1982).","journal-title":"Am. J. Psychiatry"},{"issue":"11","key":"32515_CR27","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/wnl.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris, J. C. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43(11), 2412\u20132414. https:\/\/doi.org\/10.1212\/wnl.43.11.2412-a (1993).","journal-title":"Neurology"},{"key":"32515_CR28","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/s0028-3932(01)00055-0","volume":"39","author":"R Blesa","year":"2001","unstructured":"Blesa, R. et al. Clinical validity of the \u201cmini-mental state\u201d for Spanish speaking communities. Neuropsychologia 39, 1150\u20131157. https:\/\/doi.org\/10.1016\/s0028-3932(01)00055-0 (2001).","journal-title":"Neuropsychologia"},{"key":"32515_CR29","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1001\/archneur.1975.00490510088009","volume":"32","author":"VC Hachinski","year":"1975","unstructured":"Hachinski, V. C. et al. Cerebral blood flow in dementia. Arch. Neurol. 32, 632\u2013637. https:\/\/doi.org\/10.1001\/archneur.1975.00490510088009 (1975).","journal-title":"Arch. Neurol."},{"key":"32515_CR30","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1176\/ajp.139.9.1136","volume":"139","author":"B Reisberg","year":"1982","unstructured":"Reisberg, B., Ferris, S. H., De Leon, M. J. & Crook, T. The global deterioration scale for assessment of primary degenerative dementia. Am. J. Psychiatry 139, 1136\u20131139. https:\/\/doi.org\/10.1176\/ajp.139.9.1136 (1982).","journal-title":"Am. J. Psychiatry"},{"key":"32515_CR31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1300\/J018v05n01_09","volume-title":"Clinical Gerontology: A Guide to Assessment and Intervention","author":"JI Sheikh","year":"1986","unstructured":"Sheikh, J. I. & Yesavage, J. A. Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. In Clinical Gerontology: A Guide to Assessment and Intervention (ed. Brink, T. L.) 165\u2013173 (The Haworth Press, 1986). https:\/\/doi.org\/10.1300\/J018v05n01_09."},{"key":"32515_CR32","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/wnl.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris, J. C. The clinical dementia rating (cdr): Current version and scoring rules. Neurology 43, 2412\u20132414. https:\/\/doi.org\/10.1212\/wnl.43.11.2412-a (1993).","journal-title":"Neurology"},{"issue":"512","key":"32515_CR33","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1192\/bjp.114.512.797","volume":"114","author":"G Blessed","year":"1968","unstructured":"Blessed, G., Tomlinson, B. E. & Roth, M. The association between quantitative measures of dementia and of senile changes in the cerebral gray matter of elderly subjects. Br. J. Psychiatry 114(512), 797\u2013811. https:\/\/doi.org\/10.1192\/bjp.114.512.797 (1968).","journal-title":"Br. J. Psychiatry"},{"issue":"6","key":"32515_CR34","first-page":"317","volume":"17","author":"M Boada","year":"2002","unstructured":"Boada, M., Cejudo, J. C., T\u00e0rraga, L., L\u00f3pez, O. L. & Kaufer, D. Neuropsychiatric inventory questionnaire (NPI-Q): Spanish validation of an abridged form of the Neuropsychiatric Inventory (NPI). Neurologia 17(6), 317\u2013323 (2002).","journal-title":"Neurologia"},{"issue":"2","key":"32515_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/13803395.2011.630652","volume":"34","author":"M Alegret","year":"2012","unstructured":"Alegret, M. et al. Normative data of a brief neuropsychological battery for Spanish individuals older than 49. J. Clin. Exp. Neuropsychol. 34(2), 209\u2013219. https:\/\/doi.org\/10.1080\/13803395.2011.630652 (2012) (Epub 2011 Dec 13).","journal-title":"J. Clin. Exp. Neuropsychol."},{"issue":"10","key":"32515_CR36","doi-asserted-by":"publisher","first-page":"e76436","DOI":"10.1371\/journal.pone.0076436","volume":"8","author":"M Alegret","year":"2013","unstructured":"Alegret, M. et al. Cut-off scores of a brief neuropsychological battery (NBACE) for Spanish individual adults older than 44 years old. PLoS\u00a0One 8(10), e76436. https:\/\/doi.org\/10.1371\/journal.pone.0076436 (2013).","journal-title":"PLoS\u00a0One"},{"key":"32515_CR37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1474-4422(10)70277-5","volume":"10","author":"D Kapogiannis","year":"2011","unstructured":"Kapogiannis, D. & Mattson, M. P. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer\u2019s disease. Lancet Neurol. 10, 187\u2013198. https:\/\/doi.org\/10.1016\/S1474-4422(10)70277-5 (2011).","journal-title":"Lancet Neurol."},{"key":"32515_CR38","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/STROKEAHA.108.531343","volume":"40","author":"SS Staekenborg","year":"2009","unstructured":"Staekenborg, S. S. et al. Progression of mild cognitive impairment to dementia: Contribution of cerebrovascular disease compared with medial temporal lobe atrophy. Stroke 40, 1269\u20131274. https:\/\/doi.org\/10.1161\/STROKEAHA.108.531343 (2009).","journal-title":"Stroke"},{"key":"32515_CR39","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/ptr.814","volume":"15","author":"R Bridi","year":"2001","unstructured":"Bridi, R., Crosetti, F. P., Steffen, V. M. & Henriques, A. T. The antioxidant activity of standardized extract of Gingko biloba (EGb 761) in rats. Phytother. Res. 15, 449\u2013451. https:\/\/doi.org\/10.1002\/ptr.814 (2001).","journal-title":"Phytother. Res."},{"key":"32515_CR40","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00253-003-1527-9","volume":"64","author":"JV Smith","year":"2004","unstructured":"Smith, J. V. & Luo, Y. Studies on molecular mechanisms of Ginkgo biloba extract. Appl. Microbiol. Biotechnol. 64, 465\u2013472. https:\/\/doi.org\/10.1007\/s00253-003-1527-9 (2004).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"32515_CR41","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3233\/JAD-2009-1184","volume":"18","author":"M Salkovic-Petrisic","year":"2009","unstructured":"Salkovic-Petrisic, M., Osmanovic, J., Grunblatt, E., Riederer, P. & Hoyer, S. Modeling sporadic Alzheimer\u2019s disease: The insulin resistant brain state generates multiple long-term morphobiological abnormalities including hyperphosphorylated tau protein and amyloid-beta. J. Alzheimers Dis. 18, 729\u2013750. https:\/\/doi.org\/10.3233\/JAD-2009-1184 (2009).","journal-title":"J. Alzheimers Dis."},{"key":"32515_CR42","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s007020050232","volume":"106","author":"S Hoyer","year":"1999","unstructured":"Hoyer, S., Lannert, H., Noldner, M. & Chatterjee, S. S. Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761). J. Neural Transm. (Vienna) 106, 1171\u20131188. https:\/\/doi.org\/10.1007\/s007020050232 (1999).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"32515_CR43","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3233\/JAD-2009-1189","volume":"18","author":"F Tchantchou","year":"2009","unstructured":"Tchantchou, F. et al. Stimulation of neurogenesis and synaptogenesis by bilobalide and quercetin via common final pathway in hippocampal neurons. J. Alzheimers Dis. 18, 787\u2013798. https:\/\/doi.org\/10.3233\/JAD-2009-1189 (2009).","journal-title":"J. Alzheimers Dis."},{"key":"32515_CR44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.bbi.2015.01.011","volume":"46","author":"X Liu","year":"2015","unstructured":"Liu, X. et al. Long-term treatment with Ginkgo biloba extract EGb 761 improves symptoms and pathology in a transgenic mouse model of Alzheimer\u2019s disease. Brain Behav. Immunol. 46, 121\u2013131. https:\/\/doi.org\/10.1016\/j.bbi.2015.01.011 (2015).","journal-title":"Brain Behav. Immunol."},{"key":"32515_CR45","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/978-3-662-09220-0_120","volume":"1","author":"WD Heiss","year":"1978","unstructured":"Heiss, W. D. & Zeiler, K. Medikamentoese Beeinflussung der Hirndurchblutung. Pharmakotherapie 1, 137\u2013144. https:\/\/doi.org\/10.1007\/978-3-662-09220-0_120 (1978).","journal-title":"Pharmakotherapie"},{"key":"32515_CR46","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.atherosclerosis.2007.02.021","volume":"192","author":"M Rodriguez","year":"2007","unstructured":"Rodriguez, M. et al. Reduction of atherosclerotic nanoplaque formation and size by Ginkgo biloba (EGb 761) in cardiovascular high-risk patients. Atherosclerosis 192, 438\u2013444. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2007.02.021 (2007).","journal-title":"Atherosclerosis"},{"key":"32515_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.868843","author":"R Hoerr","year":"2022","unstructured":"Hoerr, R. et al. Single and repeated doses of EGb 761 do not affect pharmacokinetics or pharmacodynamics of rivaroxaban in healthy subjects. Front. Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.868843 (2022).","journal-title":"Front. Pharmacol."},{"key":"32515_CR48","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1476-5381.2009.00580.x","volume":"159","author":"T Yoshitake","year":"2010","unstructured":"Yoshitake, T., Yoshitake, S. & Kehr, J. The Ginkgo biloba extract EGb 761 and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex. Br. J. Pharmacol. 159, 65. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00580.x (2010).","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"32515_CR49","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.jpsychires.2012.03.003","volume":"46","author":"H Herrschaft","year":"2012","unstructured":"Herrschaft, H. et al. Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: A randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J. Psychiatr. Res. 46(6), 716\u2013723. https:\/\/doi.org\/10.1016\/j.jpsychires.2012.03.003 (2012).","journal-title":"J. Psychiatr. Res."},{"issue":"11","key":"32515_CR50","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/gps.2662","volume":"26","author":"R Ihl","year":"2011","unstructured":"Ihl, R. et al. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features. A randomized controlled trial. Int. J. Geriatr. Psychiatry 26(11), 1186\u20131194. https:\/\/doi.org\/10.1002\/gps.2662 (2011).","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"2","key":"32515_CR51","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3233\/JAD-215348","volume":"86","author":"B Jens","year":"2022","unstructured":"Jens, B., Oliver, P. & Karel, K. Association between Ginkgo biloba extract prescriptions and dementia incidence in outpatients with mild cognitive impairment in Germany: A retrospective cohort study. J. Alzheimers Dis. 86(2), 703\u2013709. https:\/\/doi.org\/10.3233\/JAD-215348 (2022).","journal-title":"J. Alzheimers Dis."},{"issue":"5","key":"32515_CR52","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.trci.2019.03.001","volume":"2019","author":"T Jinzhou","year":"2019","unstructured":"Jinzhou, T. et al. Chinese herbal medicine Qinggongshoutao for the treatment of amnestic mild cognitive impairment: A 52-week randomized controlled trial. Alzheimers Dement. (N Y.) 2019(5), 441\u2013449. https:\/\/doi.org\/10.1016\/j.trci.2019.03.001 (2019) (eCollection 2019).","journal-title":"Alzheimers Dement. (N Y.)"},{"key":"32515_CR53","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/jama.2008.683","volume":"300","author":"TD Steven","year":"2008","unstructured":"Steven, T. D. et al. Ginkgo biloba for prevention of dementia: A randomized controlled trial. JAMA 300, 19. https:\/\/doi.org\/10.1001\/jama.2008.683 (2008).","journal-title":"JAMA"},{"key":"32515_CR54","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3389\/fnagi.2016.00276","volume":"8","author":"Z Hong-Feng","year":"2016","unstructured":"Hong-Feng, Z. et al. An overview of systematic reviews of ginkgo biloba extracts for mild cognitive impairment and dementia. Front. Aging Neurosci. 8, 276. https:\/\/doi.org\/10.3389\/fnagi.2016.00276 (2016) (eCollection 2016).","journal-title":"Front. Aging Neurosci."},{"key":"32515_CR55","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s12603-015-0661-2","volume":"19","author":"B Scherrer","year":"2015","unstructured":"Scherrer, B. et al. Analysing time to event data in dementia prevention trials: The example of the guidage study of EGb761. J. Nutr. Health Aging 19, 1009\u20131011. https:\/\/doi.org\/10.1007\/s12603-015-0661-2 (2015).","journal-title":"J. Nutr. Health Aging"},{"issue":"2","key":"32515_CR56","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3233\/JAD-190546","volume":"71","author":"S Matsunaga","year":"2019","unstructured":"Matsunaga, S., Fujishiro, H. & Takechi, H. Efficacy and safety of cholinesterase inhibitors for mild cognitive impairment: a systematic review and meta-analysis. J. Alzheimers Dis. 71(2), 513\u2013523. https:\/\/doi.org\/10.3233\/JAD-190546 (2019).","journal-title":"J. Alzheimers Dis."},{"issue":"8","key":"32515_CR57","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/15622975.2019.1696473","volume":"21","author":"S Kasper","year":"2020","unstructured":"Kasper, S. et al. Management of mild cognitive impairment (MCI): The need for national and international guidelines. World J. Biol. Psychiatry 21(8), 579\u2013594. https:\/\/doi.org\/10.1080\/15622975.2019.1696473 (2020) (Epub 2020 Feb 5).","journal-title":"World J. Biol. Psychiatry"},{"issue":"10","key":"32515_CR58","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1474-4422(12)70206-5","volume":"11","author":"B Vellas","year":"2012","unstructured":"Vellas, B. et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer\u2019s disease (GuidAge): A randomised placebo-controlled trial. Lancet Neurol. 11(10), 851\u2013859. https:\/\/doi.org\/10.1016\/S1474-4422(12)70206-5 (2012) (Epub 2012 Sep 6).","journal-title":"Lancet Neurol."},{"issue":"2","key":"32515_CR59","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/cns.13536","volume":"27","author":"N Kandiah","year":"2021","unstructured":"Kandiah, N. et al. Strategies for the use of Ginkgo biloba extract, EGb 761, in the treatment and management of mild cognitive impairment in Asia: Expert consensus. CNS Neurosci. Ther. 27(2), 149\u2013162. https:\/\/doi.org\/10.1111\/cns.13536 (2021) (Epub 2020 Dec 22).","journal-title":"CNS Neurosci. Ther."},{"issue":"4","key":"32515_CR60","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack, C. R. Jr. et al. NIA-AA research framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14(4), 535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018 (2018).","journal-title":"Alzheimers Dement."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32515-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32515-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32515-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T07:09:15Z","timestamp":1680505755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32515-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["32515"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-32515-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,3]]},"assertion":[{"value":"12 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5406"}}